131 related articles for article (PubMed ID: 34935528)
21. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
22. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
[TBL] [Abstract][Full Text] [Related]
23. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
[TBL] [Abstract][Full Text] [Related]
24. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
25. Association Between
Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A
Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003
[TBL] [Abstract][Full Text] [Related]
26. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
27. Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma: a meta-analysis.
Yang JZ; Ji AF; Wang JS; Chen ZY; Wen SW
Asian Pac J Cancer Prev; 2014; 15(9):3921-5. PubMed ID: 24935575
[TBL] [Abstract][Full Text] [Related]
28. Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification.
Ooft ML; van Ipenburg J; van Loo R; de Jong R; Moelans C; Braunius W; de Bree R; van Diest P; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
J Clin Pathol; 2018 Apr; 71(4):351-359. PubMed ID: 28893862
[TBL] [Abstract][Full Text] [Related]
29. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
30. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
[TBL] [Abstract][Full Text] [Related]
31. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
[TBL] [Abstract][Full Text] [Related]
32. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
[TBL] [Abstract][Full Text] [Related]
33. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.
Ge YZ; Xu LW; Jia RP; Xu Z; Feng YM; Wu R; Yu P; Zhao Y; Gui ZL; Tan SJ; Song Q
Tumour Biol; 2014 Apr; 35(4):3881-90. PubMed ID: 24353088
[TBL] [Abstract][Full Text] [Related]
34. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
36. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
37. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.
Li YS; Xie Q; Yang DY; Zheng Y
Mol Biol Rep; 2014 Jun; 41(6):3925-33. PubMed ID: 24566681
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting.
Yang X; Dai W; Kwong DL; Szeto CY; Wong EH; Ng WT; Lee AW; Ngan RK; Yau CC; Tung SY; Lung ML
Int J Cancer; 2015 Feb; 136(4):E127-35. PubMed ID: 25196065
[TBL] [Abstract][Full Text] [Related]
39. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of RASSF1A methylation for breast cancer: a meta-analysis.
Li M; Wang C; Yu B; Zhang X; Shi F; Liu X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31196964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
